Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CRDF

Cardiff Oncology (CRDF)

Cardiff Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CRDF
DateTimeSourceHeadlineSymbolCompany
03/05/202406:05GlobeNewswire Inc.Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
26/04/202406:05GlobeNewswire Inc.Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
09/04/202406:05GlobeNewswire Inc.Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyNASDAQ:CRDFCardiff Oncology Inc
08/03/202410:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202410:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202410:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202410:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
07/03/202408:05GlobeNewswire Inc.Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024NASDAQ:CRDFCardiff Oncology Inc
01/03/202408:07GlobeNewswire Inc.Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
01/03/202408:06GlobeNewswire Inc.Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCNASDAQ:CRDFCardiff Oncology Inc
01/03/202408:05GlobeNewswire Inc.Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)NASDAQ:CRDFCardiff Oncology Inc
01/03/202408:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRDFCardiff Oncology Inc
27/02/202400:00GlobeNewswire Inc.Cardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:CRDFCardiff Oncology Inc
23/02/202400:00GlobeNewswire Inc.Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
07/02/202408:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRDFCardiff Oncology Inc
18/01/202402:30PR Newswire (US)Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer ResearchNASDAQ:CRDFCardiff Oncology Inc
09/01/202401:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
21/11/202308:05PR Newswire (US)Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:CRDFCardiff Oncology Inc
03/11/202307:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
03/11/202307:05PR Newswire (US)Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
03/11/202307:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
27/10/202307:05PR Newswire (US)Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
27/09/202306:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
27/09/202306:05PR Newswire (US)Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib MonotherapyNASDAQ:CRDFCardiff Oncology Inc
05/09/202322:00PR Newswire (US)Cardiff Oncology to Present at Upcoming Investor Conferences in SeptemberNASDAQ:CRDFCardiff Oncology Inc
10/08/202306:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
10/08/202306:05PR Newswire (US)Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
10/08/202306:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
08/08/202306:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
08/08/202306:05PR Newswire (US)Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer RelationshipNASDAQ:CRDFCardiff Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:CRDF